|
 |
J Clin Outcomes Manage
2006 Mar;13(3):157-158, 161-175, 182-183
Use of dual-modality positron emission tomography/computed tomography in oncology
Ratko TA, Singh A, Cummings JP, Matuszewski KA
Abstract Objective: To review the literature relating to imaging using positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) and computed tom--ography (CT) in oncology. Methods: Search of the MEDLINE database through 30 June 2005. Results: There were 22 peer-reviewed publications in which dual-modality FDG-PET/CT was compared with CT alone, PET alone, or other imaging techniques in a total of 1596 cancer patients. Data from these studies suggest that dual-modality FDG-PET/CT is superior to either FDG-PET alone or CT alone in detecting, localizing, and characterizing a variety of cancer types. The evidence is limited in that none of the studies used a randomized controlled design in which PET or CT images obtained with stand-alone devices were compared with images acquired using dual-modality instruments. Conclusion: Although explicit patient selection guidelines for the use of dual-modality FDG-PET/CT have not been published, evidence suggests that dual-modality PET/CT may be considered medically necessary when PET is considered medically necessary for cancer patients. This technology represents a major advance in diagnostic imaging in oncology that will quickly become the standard of care.
Clinical Review
Search the Turner White index to find abstracts of articles published in JCOM.
|
